Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Lung Diseases, Interstitial
/ complications
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Paclitaxel
/ administration & dosage
Prospective Studies
carboplatin
exacerbation
interstitial lung disease
nab-paclitaxel
non-small-cell lung cancer
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
19
08
2019
revised:
06
10
2019
accepted:
09
10
2019
pubmed:
15
10
2019
medline:
18
12
2019
entrez:
15
10
2019
Statut:
ppublish
Résumé
The prognosis of non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is poor, and 5%-20% of those receiving chemotherapy experience ILD exacerbation. To evaluate the safety and efficacy of nab-paclitaxel plus carboplatin for NSCLC patients with ILD, we undertook a multicenter phase II study. Chemotherapy-naïve patients with advanced NSCLC and mild or moderate ILD received nab-paclitaxel (100 mg/m
Identifiants
pubmed: 31608537
doi: 10.1111/cas.14217
pmc: PMC6890441
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3738-3745Subventions
Organisme : Ministry of Health, Labour and Welfare
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancer Chemother Pharmacol. 2016 Jun;77(6):1245-52
pubmed: 27130459
Clin Lung Cancer. 2018 Jan;19(1):e5-e9
pubmed: 28687482
J Thorac Oncol. 2011 Jul;6(7):1242-6
pubmed: 21623239
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43
pubmed: 17585107
Intern Med. 2009;48(9):665-72
pubmed: 19420811
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Anticancer Res. 2015 Jul;35(7):4259-63
pubmed: 26124387
Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct;22(3):167-74
pubmed: 16315778
Cancer Chemother Pharmacol. 2015 Mar;75(3):521-6
pubmed: 25563718
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Mol Clin Oncol. 2017 Oct;7(4):604-608
pubmed: 28855994
Lung Cancer. 2011 Jan;71(1):70-4
pubmed: 20493578
Oncol Lett. 2012 Sep;4(3):477-482
pubmed: 23741246
Lung Cancer. 2016 Jun;96:63-7
pubmed: 27133752
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
Br J Cancer. 2004 Aug;91 Suppl 2:S18-23
pubmed: 15340374
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
Anticancer Res. 2015 Mar;35(3):1697-701
pubmed: 25750330
Jpn J Clin Oncol. 2018 Jan 1;48(1):89-93
pubmed: 29036303
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Cancer Sci. 2019 Dec;110(12):3738-3745
pubmed: 31608537
J Thorac Oncol. 2016 Dec;11(12):2141-2149
pubmed: 27575421
Anticancer Res. 2010 Oct;30(10):4357-61
pubmed: 21036764
Anticancer Res. 2012 Dec;32(12):5475-80
pubmed: 23225454